CIRM

Patient Advocate Leads Drive to Add Rare Diseases to CIRM’s Stem Cell Bank

November 1, 2016 Oakland, CA – Christina Waters is a rare kind of person: creative, compassionate, and committed to creating change. Now she is using those rare talents to help children battling rare diseases. She is helping add blood and skin samples from these children to be turned into stem cells and used as a resource for researchers to better understand …

Trials supported by electronic health records

Trials supported by electronic health records – a game-changer for study design and execution Professor Martin Gibson will be revealing the secrets of the successful delivery of GlaxoSmithKline’s (GSK) real world Salford Lung Study at BioData World Congress 2016 on 26 October in Cambridge. Widely recognised as the first study of its kind globally, the Salford Lung Study is a …

Rare diseases

Sharing the mission to conquer rare diseases

Closer collaboration between pharmaceutical companies and patient organizations will accelerate drug development At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases. Advocacy groups rely on their partners for financial and scientific support while providing access to repositories of patient data – the key to understanding rare diseases …

Diagnosis in neurosurgery

Remote intra-operative diagnosis in neurosurgery

Graham McHardy CSci FIBMS Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK   The introduction of digital slide scanning for remote reporting has restored an important service for patient healthcare at a Scottish hospital Telepathology is the process of digitising histological images for transmission electronically to remote centres, often for the purposes of diagnosis. Some telepathology systems employ robotic microscopes, which can be controlled remotely in order …

Patient, Registries, Evidence, Value, Evidence Europe

How can patient registries add value to evidence based decision making?

At Evidence EU 2014, Dr. Päivi Hämäläinen, Director of Department of Information, National Institute of Health and Welfare, Finland, gave a presentation “How can patient registries add value to evidence based decision making?” Dr. Päivi Hämäläinen’s presentation depicts her theoretical vision: data is created during patient visits to care and can be secondarily used for research, planning and decision making. Download and …

patient, outcomes

How can patient reported outcomes generate evidence to validate health claims?

At Evidence EU 2014, Tara Symonds , Senior Director, Pfizer, gave a presentation on  “How can patient reported outcomes generate evidence to validate health claims?” Symonds’ presentation reveals her belief that PRO data is increasingly seen as important by payers for validating health claims from a patient perspective. She also mentions both the EU HTA community and US Federal government calling for …

Download: Payer Engagement and Preparing Information to Support Value Proposition

Demonstrate value and improve payer engagement with tips from Jorge Arellano, MSc, MPhil, Director Global Health Economics, Amgen. In his presentation, given at Evidence USA 2013, he discusses these topics and more. Download to learn: Evidence Generation: The Process Evidence Generation: Key Deliverables Payers input Understanding Your Payer(s) Download presentation Discover how pharma, payers and patients are utilizing real world …

andrew schorr, patient, opinion, pharma, patient power

Patient Opinion Leaders: Andrew Schorr

First published on pharmaphorum.com on 8th August 2014, reproduced here by kind permission. As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the pharmaphorum report, ‘Patient Opinion Leaders: The new KOLs for pharma?’ In this video he talks about how POLs are starting to have …

video, patient, strategy, safety, patient safety, drug safety

Big opportunities for improving patient safety

What is Pharma’s biggest opportunity for improving patient safety over the next 5-10 years?  This question was posed to several attendees at last year’s World Drug Safety Congress Europe event.  Watch the video for their answers. Hear from: Christina Stoem Moeller, Astra Zeneca Logesvaran Yogendran, Janssen Pharmaceuticals Logesvaran Yogendran, Janssen Pharmaceuticals Marqus Hamwright, UCB Pharma Dr Simon Ingate, Pope Woodhead …

Download ebook: Top tips for customer engagement

In an era of austerity, governments are focusing on value. Value is being defined by primary and secondary health outcomes for citizens, and medicines are just part of the treatment. This is forcing pharma to adopt a broader context in their promotional models, integrating services into the mix, providing patient support and increasing patient empowerment so that products are used …